Senseonics Holdings, Inc.

Senseonics Holdings, Inc. is a medical technology company dedicated to the development, manufacturing, and commercialization of continuous glucose monitoring (CGM) systems for individuals with diabetes. The company's mission is to transform lives within the global diabetes community through its differentiated, long-term implantable glucose management technology. Headquartered in Germantown, Maryland, Senseonics focuses on providing innovative solutions for diabetes management. [2, 5, 8, 9, 10, 21, 22, 28, 34]

The company's primary product line includes the Eversense, Eversense XL, Eversense E3, and Eversense 365 implantable CGM systems. These systems measure glucose levels via a small sensor inserted under the skin, which communicates with a removable and rechargeable smart transmitter worn over the sensor, and a mobile application for real-time data monitoring. A key differentiator is the extended wear time of its sensors, with Eversense 365 being the world's first and only one-year implantable CGM, significantly reducing the frequency of sensor changes compared to other systems. [2, 5, 8, 9, 10, 20, 21, 28, 30]

In recent developments, Senseonics announced an $80 million public offering of common stock and pre-funded warrants on April 30, 2026, to support the ongoing launch of Eversense 365 and future product development. [9, 11, 19, 22, 23, 33] The company also initiated the European launch of Eversense 365 in April 2026, following its CE Mark approval in January 2026 and U.S. FDA approval in September 2024. [20] Furthermore, Senseonics is transitioning to a self-commercialization model for Eversense 365, taking over global sales and marketing from its partner Ascensia Diabetes Care starting January 1, 2026, a strategic move aimed at accelerating growth and improving gross margins. [26, 29] Timothy T. Goodnow serves as the President, CEO, and Director of Senseonics Holdings, Inc. [2, 6, 8, 12, 15]

Latest updates

Senseonics Raises $80 Million via Stock Offering, Warrants

Event summary

  • Senseonics priced an $80 million public offering consisting of 8 million shares of common stock at $5.00 per share.
  • The offering also includes pre-funded warrants for 8 million shares at $4.999 per warrant.
  • TD Cowen and Barclays are joint book-running managers, with Mizuho and Lake Street acting as bookrunners.
  • Senseonics has a 30-day option to issue an additional 2.4 million shares.
  • Proceeds will fund Eversense 365 launch, pipeline development, and general corporate purposes.

The big picture

Senseonics' capital raise underscores the ongoing need for funding within the medical device sector, particularly for companies focused on long-term implantable technologies. The use of pre-funded warrants suggests a degree of investor skepticism regarding the company's near-term performance, as it allows investors to participate in future upside while mitigating initial risk. This offering provides a short-term boost to the company's liquidity but also introduces dilution for existing shareholders, placing increased pressure on operational execution.

What we're watching

Execution Risk
The success of the Eversense 365 launch and its contribution to revenue growth will be critical to justifying the capital raise and mitigating dilution for existing shareholders.
Market Dynamics
The ongoing competitive landscape within the CGM market will influence Senseonics’ ability to gain market share and achieve sustainable growth, particularly given the presence of larger, more established players.
Financial Health
The company's ability to manage its burn rate and achieve profitability will be essential to maintaining investor confidence and avoiding the need for further capital raises.

Senseonics Launches $80 Million Stock Offering to Fuel CGM Expansion

Event summary

  • Senseonics Holdings initiated an $80 million public offering of common stock and pre-funded warrants.
  • The offering includes a potential 15% over-allotment option, totaling up to $92 million.
  • TD Cowen and Barclays are joint book-running managers, with Mizuho and Lake Street acting as bookrunners.
  • Proceeds will be used to fund the launch of Eversense 365, pipeline development, and general corporate purposes.
  • The offering is made under a 'shelf' registration statement filed with the SEC on August 6, 2025, and effective August 18, 2025.

The big picture

Senseonics’ capital raise underscores the ongoing need for funding in the CGM market, where competition is intensifying. The reliance on a 'shelf' offering suggests a desire for flexibility and speed, but also potentially indicates a lack of alternative funding sources. The company’s ability to execute on its growth plans and achieve profitability will be paramount in justifying this significant equity dilution.

What we're watching

Execution Risk
The success of Eversense 365’s launch and adoption will be critical to justifying the capital raise and demonstrating a return on investment for new shareholders.
Dilution Impact
The extent of the over-allotment option’s exercise will significantly impact existing shareholders’ ownership and potentially depress the stock price in the near term.
Market Conditions
The offering’s completion hinges on prevailing market conditions, which remain sensitive to macroeconomic factors and investor sentiment toward medical technology companies.

Senseonics Launches Year-Long CGM in Europe, Eyes 30M Patient Market

Event summary

  • Senseonics launched Eversense 365, its one-year implantable CGM, in Sweden on April 24, 2026, with planned launches in Germany, Spain, and Italy in the coming weeks.
  • Eversense 365 doubles the sensor lifespan of the previous Eversense E3 model, extending monitoring from six months to a full year.
  • The launch follows CE Mark approval in January 2026 and builds on commercial momentum in the U.S.
  • Senseonics estimates the European market represents a total addressable market of over 30 million patients.

The big picture

Senseonics’ European launch represents a significant expansion for the company, moving beyond its established U.S. market. The introduction of a year-long CGM addresses a key pain point for patients and clinicians, potentially disrupting the traditional short-term CGM market. However, success hinges on navigating complex European regulatory and reimbursement landscapes, and demonstrating a clear clinical and economic advantage over existing solutions.

What we're watching

Commercialization
The speed of adoption across Germany, Spain, and Italy will be key to assessing the true market demand for a year-long implantable CGM.
Reimbursement
European reimbursement policies will significantly impact Eversense 365’s uptake, and the company’s ability to secure favorable coverage will be crucial for long-term success.
Integration
The success of the integration with Sequel Med Tech’s automated insulin delivery system will determine if Eversense can become a central hub for diabetes management.
CID: 2533